General Information of Drug (ID: DMYEMWB)

Drug Name
PMID22533316C1 Drug Info
Synonyms GTPL6709
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
44570860
TTD Drug ID
DMYEMWB

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Discontinued Drug(s)
Investigative Drug(s)
Drug(s) Targeting Lanosterol synthase (LSS)
Drug Name Drug ID Indication ICD 11 Highest Status REF
ZD-9720 DMFV47R Arteriosclerosis BD40 Terminated [2]
BIBB-515 DM6QT9P Arteriosclerosis BD40 Terminated [3]
BIBX-79 DMRXWCO Arteriosclerosis BD40 Terminated [4]
B-Octylglucoside DMMO75G Discovery agent N.A. Investigative [5]
Lanosterol DMHN74V Discovery agent N.A. Investigative [5]
PMID22533316C4 DMW3UHO Discovery agent N.A. Investigative [1]
PMID9003518C4 DMYE64O Discovery agent N.A. Investigative [6]
29-methylidene-2,3-oxidosqualene DMUQAP7 Discovery agent N.A. Investigative [6]
Tetradecane DMK8P61 Discovery agent N.A. Investigative [5]
PMID9003518C3 DM1I578 Discovery agent N.A. Investigative [6]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Lanosterol synthase (LSS) TT7O8ZA ERG7_HUMAN Inhibitor [1]

References

1 Cytotoxic effects of combination of oxidosqualene cyclase inhibitors with atorvastatin in human cancer cells. J Med Chem. 2012 Jun 14;55(11):4990-5002.
2 Toxicologic lesions associated with two related inhibitors of oxidosqualene cyclase in the dog and mouse. Toxicol Pathol. 2001 Mar-Apr;29(2):174-9.
3 Effects of a novel 2,3-oxidosqualene cyclase inhibitor on cholesterol biosynthesis and lipid metabolism in vivo. J Lipid Res. 1997 Mar;38(3):564-75.
4 Effects of a novel 2,3-oxidosqualene cyclase inhibitor on the regulation of cholesterol biosynthesis in HepG2 cells. J Lipid Res. 1996 Jan;37(1):148-58.
5 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
6 Synthesis and inhibition studies of sulfur-substituted squalene oxide analogues as mechanism-based inhibitors of 2,3-oxidosqualene-lanosterol cyclase. J Med Chem. 1997 Jan 17;40(2):201-9.